KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Treasury Shares (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Treasury Shares for 8 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 14.23% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, up 14.23% year-over-year, with the annual reading at $5.7 million for FY2025, 14.23% up from the prior year.
  • Treasury Shares hit $5.7 million in Q4 2025 for Vir Biotechnology, up from $5.0 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $5.7 million in Q4 2025 to a low of $1852.0 in Q2 2021.
  • Historically, Treasury Shares has averaged $2.6 million across 5 years, with a median of $2.7 million in 2022.
  • Biggest five-year swings in Treasury Shares: tumbled 99.78% in 2021 and later skyrocketed 7452.44% in 2022.
  • Year by year, Treasury Shares stood at $1.3 million in 2021, then soared by 109.84% to $2.7 million in 2022, then skyrocketed by 80.11% to $4.8 million in 2023, then increased by 3.67% to $5.0 million in 2024, then increased by 14.23% to $5.7 million in 2025.
  • Business Quant data shows Treasury Shares for VIR at $5.7 million in Q4 2025, $5.0 million in Q4 2024, and $4.8 million in Q4 2023.